Concurrent Investment Advisors LLC Buys 3,161 Shares of IQVIA Holdings Inc. $IQV

Concurrent Investment Advisors LLC lifted its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV) by 36.0% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 11,948 shares of the medical research company’s stock after purchasing an additional 3,161 shares during the period. Concurrent Investment Advisors LLC’s holdings in IQVIA were worth $2,693,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in IQV. Ameliora Wealth Management Ltd. bought a new stake in shares of IQVIA during the 4th quarter valued at about $25,000. Physician Wealth Advisors Inc. raised its stake in IQVIA by 1,340.0% during the 3rd quarter. Physician Wealth Advisors Inc. now owns 144 shares of the medical research company’s stock worth $27,000 after buying an additional 134 shares during the period. Westside Investment Management Inc. raised its stake in IQVIA by 219.6% during the 3rd quarter. Westside Investment Management Inc. now owns 147 shares of the medical research company’s stock worth $30,000 after buying an additional 101 shares during the period. Measured Wealth Private Client Group LLC acquired a new position in IQVIA during the 3rd quarter worth approximately $30,000. Finally, Atlantic Union Bankshares Corp bought a new position in shares of IQVIA in the third quarter valued at approximately $36,000. Institutional investors own 89.62% of the company’s stock.

IQVIA Price Performance

NYSE:IQV opened at $159.04 on Wednesday. The firm has a market capitalization of $26.99 billion, a price-to-earnings ratio of 20.23, a P/E/G ratio of 1.63 and a beta of 1.39. IQVIA Holdings Inc. has a 52-week low of $134.65 and a 52-week high of $247.04. The stock has a fifty day moving average of $169.86 and a 200 day moving average of $202.19. The company has a debt-to-equity ratio of 2.09, a quick ratio of 0.75 and a current ratio of 0.75.

IQVIA (NYSE:IQV) last posted its quarterly earnings data on Thursday, February 5th. The medical research company reported $3.42 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.40 by $0.02. The company had revenue of $4.36 billion during the quarter, compared to analyst estimates of $4.24 billion. IQVIA had a return on equity of 30.50% and a net margin of 8.34%.The firm’s quarterly revenue was up 10.3% on a year-over-year basis. During the same quarter last year, the company earned $3.12 earnings per share. IQVIA has set its FY 2026 guidance at 12.550-12.850 EPS. On average, research analysts expect that IQVIA Holdings Inc. will post 11.5 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts have recently weighed in on the company. Evercore restated an “outperform” rating and issued a $185.00 target price on shares of IQVIA in a report on Wednesday, April 8th. JPMorgan Chase & Co. decreased their target price on IQVIA from $255.00 to $225.00 and set an “overweight” rating for the company in a research report on Friday, February 6th. Weiss Ratings reiterated a “hold (c)” rating on shares of IQVIA in a research report on Tuesday, April 21st. Stifel Nicolaus dropped their price objective on IQVIA from $273.00 to $220.00 and set a “buy” rating for the company in a research note on Friday, February 6th. Finally, Truist Financial dropped their price objective on IQVIA from $290.00 to $245.00 and set a “buy” rating for the company in a research note on Thursday, February 19th. Two research analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average price target of $226.63.

IQVIA Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.